Paragon 28 Inc
Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. The company offers forefoot systems, including gorilla precision MTP plating system, gorilla precision lapidus plating system, phantom lapidus intramedullary nail system, Bun-Yo-Matic lapidus clamp, and precision MIS screw system; and fracture fixation systems comprising gor… Read more
Paragon 28 Inc (FNA) - Net Assets
Latest net assets as of December 2024: $130.59 Million USD
Based on the latest financial reports, Paragon 28 Inc (FNA) has net assets worth $130.59 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($290.72 Million) and total liabilities ($160.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $130.59 Million |
| % of Total Assets | 44.92% |
| Annual Growth Rate | 36.79% |
| 5-Year Change | 82.68% |
| 10-Year Change | N/A |
| Growth Volatility | 87.72 |
Paragon 28 Inc - Net Assets Trend (2019–2024)
This chart illustrates how Paragon 28 Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Paragon 28 Inc (2019–2024)
The table below shows the annual net assets of Paragon 28 Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $130.59 Million | -26.53% |
| 2023-12-31 | $177.74 Million | +26.12% |
| 2022-12-31 | $140.93 Million | -26.67% |
| 2021-12-31 | $192.19 Million | +168.86% |
| 2020-12-31 | $71.48 Million | +162.35% |
| 2019-12-31 | $27.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Paragon 28 Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1931.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $837.00K | 0.64% |
| Other Comprehensive Income | $-807.00K | -0.62% |
| Other Components | $308.84 Million | 236.50% |
| Total Equity | $130.59 Million | 100.00% |
Paragon 28 Inc Competitors by Market Cap
The table below lists competitors of Paragon 28 Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Oppenheimer Holdings Inc
NYSE:OPY
|
$578.48 Million |
|
Capital City Bank Group
NASDAQ:CCBG
|
$578.56 Million |
|
A.G. BARR p.l.c
PINK:BAGFF
|
$578.72 Million |
|
Peijia Medical Limited
PINK:PEJMF
|
$578.72 Million |
|
GRINM Semiconductor Materials Co. Ltd. A
SHG:688432
|
$578.35 Million |
|
RPC Inc
NYSE:RES
|
$577.75 Million |
|
Aris Water Solutions Inc
NYSE:ARIS
|
$577.25 Million |
|
SmartFinancial, Inc.
NYSE:SMBK
|
$577.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Paragon 28 Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 177,741,000 to 130,586,000, a change of -47,155,000 (-26.5%).
- Net loss of 54,639,000 reduced equity.
- Other comprehensive income decreased equity by 939,000.
- Other factors increased equity by 8,423,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-54.64 Million | -41.84% |
| Other Comprehensive Income | $-939.00K | -0.72% |
| Other Changes | $8.42 Million | +6.45% |
| Total Change | $- | -26.53% |
Book Value vs Market Value Analysis
This analysis compares Paragon 28 Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.35x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 36.69x to 8.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.36 | $13.09 | x |
| 2020-12-31 | $0.94 | $13.09 | x |
| 2021-12-31 | $2.51 | $13.09 | x |
| 2022-12-31 | $1.84 | $13.09 | x |
| 2023-12-31 | $2.17 | $13.09 | x |
| 2024-12-31 | $1.57 | $13.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Paragon 28 Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -41.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -21.33%
- • Asset Turnover: 0.88x
- • Equity Multiplier: 2.23x
- Recent ROE (-41.84%) is below the historical average (-18.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 11.44% | 2.93% | 1.43x | 2.74x | $392.20K |
| 2020 | 3.76% | 2.42% | 1.14x | 1.37x | $-4.46 Million |
| 2021 | -7.12% | -9.29% | 0.63x | 1.22x | $-32.91 Million |
| 2022 | -47.77% | -37.12% | 0.71x | 1.80x | $-81.42 Million |
| 2023 | -26.92% | -22.11% | 0.64x | 1.92x | $-65.62 Million |
| 2024 | -41.84% | -21.33% | 0.88x | 2.23x | $-67.70 Million |
Industry Comparison
This section compares Paragon 28 Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Paragon 28 Inc (FNA) | $130.59 Million | 11.44% | 1.23x | $578.40 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |